To access this element change to forms mode OFF
Grant Award View - GA214903
Developing HCK inhibitor drugs to improve immunotherapy
GA ID:
GA214903
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
21-Nov-2021
Publish Date:
24-Jan-2022
Category:
Health and Medical Research
Grant Term:
1-Jan-2022 to 31-Jan-2025
Value (AUD):
$1,003,243.56
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 20/21 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
Developing HCK inhibitor drugs to improve immunotherapy
Purpose:
Anti-tumour immune responses are modulated by a cell type called macrophages, which suppress the effects of immunotherapy. We identified a molecule called HCK, which induces macrophages to inhibit the anti-tumour immune response.
In collaboration with SYNthesis and the Cancer Therapeutics CRC we will develop inhibitors for HCK. We will test these compounds in preclinical
cancer models to identify the most effective combination with immunotherapies to provide the greatest patient benefits.
In collaboration with SYNthesis and the Cancer Therapeutics CRC we will develop inhibitors for HCK. We will test these compounds in preclinical
cancer models to identify the most effective combination with immunotherapies to provide the greatest patient benefits.
GO ID:
GO Title:
NHMRC Development Grants 2021 for funding in 2022
Internal Reference ID:
2021/GNT2014063
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
La Trobe University
Recipient ABN:
64 804 735 113
Grant Recipient Location
Suburb:
Bundoora
Town/City:
Bundoora
Postcode:
3083
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA